AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03045068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FFP and Cryoprecipitate
Description: 1. 1 unit of cryoprecipitate administered during MUF and or after MUF as needed~2. FFP transfusion 10ml/kg during MUF and or after MUF as needed
Study NCT03045068 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRBC and cell saver Transfusion
Description: 1. Transfuse for target Hematocrit > 40 in neonates with SV physiology; Transfuse for Hematocrit> 33 for 2-Ventricle physiology
Study NCT03045068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRBC and cell saver Transfusion
Description: 1. Transfuse for target Hematocrit > 40 in neonates with SV physiology; Transfuse for Hematocrit> 33 for 2-Ventricle physiology
Study NCT03045068 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Factor Concentrate (Bebulin)
Description: 1. Based on clinical bleeding and achievement of hemostasis
Study NCT03045068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Factor Concentrate (Bebulin)
Description: 1. Based on clinical bleeding and achievement of hemostasis
Study NCT06609382 — intervention group
Intervention type: OTHER
Intervention: Patients had a higher left ventricular mass index or not （the exact value is determined by the cut-off value for the clinical outcomes)
Description: Patients were grouped by the cutoff value of left ventricular mass index (LVMI) for all cause death, and the Maximally Selected Rank Statistics method was used to determine the optimal cutoff point of LVMI for death.
Study NCT06609564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: Inspiratory muscle training with a pressure-adjustable device
Study NCT06609564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convantional chest physiotherapy
Description: Chest physiotherapy
Study NCT01313117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid
Description: The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
Study NCT04665570 — intervention group
Intervention type: DRUG
Intervention: BAY81-9783 (Acarbose/Metformin)
Description: Tablet (FDC of 25/50mg acarbose + 500mg metformin), three times daily
Study NCT04310384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ShuttleScope
Description: Alternative intervention
Study NCT04310384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MacIntosh Laryngoscope
Description: Gold Standart
Study NCT03224351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659
Description: Tablet for oral administration.
Study NCT03224351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: TEZ/IVA fixed-dose combination tablet for oral administration.
Study NCT03224351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: TEZ/IVA fixed-dose combination tablet for oral administration.
Study NCT03224351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT03224351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Tablet for oral administration.
Study NCT03224351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-659/TEZ/IVA)
Description: Placebo matched to VX-659 and TEZ/IVA.
Study NCT03224351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ
Description: Tablet for oral administration.
Study NCT03224351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-561
Description: Tablet for oral administration.
Study NCT03224351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-659/TEZ/VX-561)
Description: Placebo matched to VX-659, TEZ and VX-561.
Study NCT04541784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WOMAN-PRO III
Description: Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III.
Study NCT04541784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Three counselling sessions with gynaecology-oncology nurses
Description: Standardized care, three counselling sessions with a gynaecology-oncology nurse.
Study NCT01835938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1- Erlotinib
Description: * Erlotinib 50 mg tablet by mouth every day for 14 days,~* Erlotinib 100 mg tablet by mouth every day for 14 days,~* Erlotinib 150 mg tablet by mouth every day for 14 days,
Study NCT01835938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: * Placebo 50 mg tablet by mouth every day for 14 days,~* Placebo 100 mg tablet by mouth every day for 14 days,~* Placebo 150 mg tablet by mouth every day for 14 days,
Study NCT01007643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Fit (TM) Interactive Video Game
Description: Use of interactive video game exercise program on a daily basis focusing on quadriceps and hamstring flexibility along with VMO strengthening.
Study NCT01007643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Home Exercise Program
Description: Completion of daily home exercise program for quadriceps and hamstring flexibility and VMO strengthening.
Study NCT03605173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: free vitamin d test
Description: using the patient's blood serum ELISA test for free vitamin d can be performed
Study NCT03605173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: total vitamin d
Description: routinely measured from serum
Study NCT02037633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl IV
Study NCT02037633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block
Description: Fascia iliaca compartment block using ropivacaine
Study NCT02037633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Study NCT03190447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquacel Surgical®
Description: Measuring the skin integrity with each dressing and the patient satisfaction
Study NCT03190447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Border post-op®
Description: Measuring the skin integrity with each dressing and the patient satisfaction
Study NCT03190447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opsite post-op visible®
Description: Measuring the skin integrity with each dressing and the patient satisfaction
Study NCT03190447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgotul ABSORB border silicona®
Description: Measuring the skin integrity with each dressing and the patient satisfaction
Study NCT03190447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dressing
Description: Measuring the skin integrity with each dressing and the patient satisfaction
Study NCT00640133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active DBS
Description: In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.
Study NCT00640133 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active DBS
Description: In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.
Study NCT00640133 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham DBS
Description: In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will mimic adjusting the settings of the electrical stimulation. After a post-operative rest, participants will receive DBS treatment after a delay of several months. Afterwards, all participants will receive open-label long-term DBS.
Study NCT03086525 — intervention group
Intervention type: OTHER
Intervention: Diagnosis/Prognosis
Description: The present study will be a prospective observational study of 4 years that will be carried out between September 2017 and September 2020 at the University of Malaga. Several questionnaires assessing different beliefs associated with pain will be administered to participants. The results will be evaluated at baseline (t1) and in 4 follow-ups (at 12 (t2), 24 (t3), 36 (t4) and 48 (t5) months.
Study NCT00472160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Invasive Ventilation
Description: Non Invasive Ventilation
Study NCT03980080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE-127
Description: mAb antagonist to CD127 receptor (or IL-7Rα)~Group 8-9~2 escalating dose level groups IV
Study NCT02153086 — intervention group
Intervention type: DRUG
Intervention: Ramelteon
Description: Ramelteon tablets 8 mg
Study NCT03840018 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Letter by post to patients
Description: Patients received an informative letter by post, in which their doctor invited them to seek an appointment for a medication review
Study NCT02040324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask with gastric access
Study NCT02040324 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Study NCT03303963 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line
Description: Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:~* Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)~* Validating the Molbio Truenat test as a point of care test (Study 1 - phase 2)~* Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)
Study NCT03303963 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis
Description: Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:~* FDA microscopy~* Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin~* Measurement of pre-rRNA synthesis
Study NCT03860649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.
Study NCT03860649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jogging
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.
Study NCT03860649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.
Study NCT03860649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Training
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.
Study NCT02651207 — intervention group
Intervention type: OTHER
Intervention: Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant
Study NCT02170623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule I
Description: 25 mg BIBR 1048 MS
Study NCT02170623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule K
Description: 50 mg BIBR 1048 MS
Study NCT02170623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40 mg pantoprazole
Study NCT02170623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS drinking solution
Description: 50 mg BIBR 1048 MS powder plus solution
Study NCT02187419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis
Description: Hypnosis is a promising, but under-studied non-pharmacological treatment option for poor sleep during the menopausal transition. Hypnosis is a mind-body therapy that may be defined as a deeply relaxed state involving mental imagery and suggestion. The hypnotic state has been described variously as being an altered state of consciousness, focused attention, imaginative involvement, and role assumption.~However, it is generally agreed that hypnosis is a state or condition, which occurs when appropriate suggestions elicit distortions of perception, memory, or mood. Research has shown that most people are hypnotizable. Hypnosis intervention for managing chronic symptoms usually involves a hypnotic induction, instruction in self-hypnosis and practice using audio recordings.
Study NCT04379856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM-002
Description: NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)
Study NCT02642185 — intervention group
Intervention type: PROCEDURE
Intervention: Microwave ablation
Description: CT-guided percutaneous ablation of 1-5, \<31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
Study NCT02642185 — intervention group
Intervention type: PROCEDURE
Intervention: Resection
Description: Open or laparoscopic resection of liver metastases using standard of care surgical procedures
Study NCT05100550 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc is given as written in the arm description, two hours after lunch
Study NCT05100550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will not receive zinc
Study NCT04166422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation program
Description: Aerobic treatment plus strength exercises
Study NCT04166422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Description: Aerobic treatment plus strengh exercises plus virtual reality
Study NCT00587314 — intervention group
Intervention type: OTHER
Intervention: Biopsy
Description: Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus
Study NCT00853307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib capsules
Study NCT03040544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LTB-Curriculum
Description: The Lübeck Toolbox (LTB) curriculum has a structured training program, in which the laparoscopic basic skills are to be learned in six consecutive exercises. In doing so, the curriculum has precise targets for each of the six exercises based on the abilities of 15 MIS experts as a benchmark. The LTB curriculum is thus a structured training program with clear objectives that enable the technical learning of MIS basic skills comparable to the expert level.
Study NCT03040544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Performing Laparoscopic cholecystectomy by surgical residents without previous experience in MIS
Study NCT03040544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Performing Laparoscopic cholecystectomy by surgical residents without previous experience in MIS
Study NCT02135432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT02135432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04681443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystallized phenol application
Description: Crystallized phenol application into the sinus tract
Study NCT00667199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
Study NCT00643747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)
Description: Single subretinal injection of vector suspension; up to 3x10e12 vector particles
Study NCT04155762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pin Suspension System (a prosthetic suspension system)
Description: Participants used the PSS for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period.
Study NCT04155762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vacuum-Assisted Suspension System (a prosthetic suspension system)
Description: After PSS, participants employed the VASS for three months after a similar training period.
Study NCT00080535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMB-2
Description: 30 micrograms/kg every other day (QOD) x 3 every 4 weeks
Study NCT01002339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus with rapid steroid withdrawal
Description: * Basiliximab induction (4 mg i.v., days 0 and 4).~* Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.~* Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d.
Study NCT01002339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus with steroids minimization
Description: * Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d.
Study NCT01002339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA with steroid minimization
Description: * Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d
Study NCT04369573 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Early intra-aortic balloon pump (IABP) implantation
Description: IABP implantation within 6 hours since cardiogenic shock symptoms onset
Study NCT04369573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care as vasoactive agent
Description: Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20.
Study NCT00807911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant FL
Description: 5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
Study NCT00807911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant FOLFOX
Description: oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
Study NCT03207971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage treatment with subepithelial connective tissue graft
Description: Periodontal plastic surgery aiming root coverage by palatal tissue graft removed from an area with predominance of lamina propria and predominance of submucosa.
Study NCT01253278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2393910
Description: as capsules, administered orally once daily for two weeks
Study NCT01253278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as capsules, administered orally once daily for two weeks
Study NCT03557294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0mg Varenicline b.i.d.
Description: Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.